Tibet Pharmaceutical (600211.SH) announced first-half results, with net profit of 608 million yuan to mother, an increase of 7.16% over the previous year

According to the Zhitong Finance App, Tibet Pharmaceutical (600211.SH) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 1,554 billion yuan, a year-on-year decrease of 5.83%. Achieved net profit of 608 million yuan attributable to shareholders of listed companies, an increase of 7.16% over the previous year. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 440 million yuan, a year-on-year decrease of 19.00%. Basic earnings per share were $1.91.

During the reporting period, the company's revenue decreased by 5.83% year on year, and net profit attributable to shareholders of listed companies increased by 7.16% year on year. The main reason for the inconsistent change ratio was an increase of 155.96 million yuan in industrial support payments received by the company during the reporting period compared to the same period last year. Furthermore, net profit attributable to shareholders of listed companies, after deducting non-recurring profit and loss, fell 19.00% year on year. The decline exceeded the decline in operating income. The main reason was that the company continued to increase investment in R&D.